MedTrace Logo

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

NCT07093476 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2025-08-11

No results posted yet for this study

Summary

Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.

Conditions

  • T2DM
  • Diabete Type 2
  • DM

Interventions

DRUG

Metformin

tablets, QD, oral administration

DRUG

Alogliptin

tablets, QD, oral administration

DRUG

empagliflozin

tablets, QD, oral administration

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-18
Primary Completion
2026-12-31
Completion
2027-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07093476 on ClinicalTrials.gov